Last updated: 2026-10-14 20:29:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
AnaptysBio, Inc. (ANAB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $46.64, with a market capitalization of $1.38B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $30.27 to $73.30. This page covers its latest market performance, valuation, price trends and company information.
$1.38B | |
$45.25 | |
$134.00 | |
$10.00 | |
$45.59 | |
422.61K | |
541.15K | |
-- | |
$73.30 | |
$30.27 | |
-- | |
-- |
AnaptysBio, Inc. (ANAB) is trading at $46.67 in after-hours trading as of 2026-10-14 19:59:46, up 2.36% ($1.07) from the regular-session close of $45.59.
After-hours trading shows how investors are pricing ANAB after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, AnaptysBio, Inc. (ANAB) moved from $49.20 to $46.64, representing a decline of 5.21% ($2.56).
The stock traded between $44.74 and $49.84 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 546.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.0%
ANAB is currently trading at $46.64, placing it 38.0% of the way from its 52-week low of $30.27 to its 52-week high of $73.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 104 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AnaptysBio, Inc. (ANAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.